Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2016 - 2026)

Insight Molecular Diagnostics has reported Other Non-Current Assets for 11 years, with the latest figure at $574000.0 in Q1 2026.

• Quarterly Other Non-Current Assets fell 66.24% year-over-year to $574000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $574000.0 (down 66.24% YoY) and the FY2025 annual result came in at $607000.0, down 64.29% from the prior year.
• Other Non-Current Assets slipped to $574000.0 in Q1 2026 per IMDX's latest filing, from $607000.0 in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.7 million in Q2 2022 and troughed at $298000.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.7 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets tumbled 94.27% in 2022, then surged 470.47% in 2023.
• Over 5 years, Other Non-Current Assets stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then sank by 64.29% to $607000.0 in 2025, then dropped by 5.44% to $574000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $574000.0, $607000.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.